Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study
Year: 2025
Type: article
Study design: Observational Study
Abstract: Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.
DOI: 10.1093/ced/llaf342
Authors: Tiago Torres, Siddhartha Sood, Orhan Yilmaz, Ronald B Vender, Vimal H Prajapati, Luis Puig, Matteo Megna, Angelo Valerio Marzano, Paolo Gisondi, Jose-Manuel Carrascosa, Esteban Dauden, Mar Llamas-Velasco, Anna Balato, Barbara Guerra Leal, Francesca Prignano, Francesco Bellinato, Gianmarco Silvi, Eugenia Veronica Di Brizzi, Luca Potestio, Andrea Sechi, Carlo Giovanni Carrera, Anna López-Ferrer, Elena Del-Alcazar, Asfandyar Mufti, Lara Valeska Maul, Stefano Piaserico, Julia- Tatjana Maul, Jensen Yeung
Institutions: Universidade do Porto, Hospital de Santo António, Instituto de Ciências Biomédicas Albel Salazar, University of Toronto, University of Saskatchewan, Dermatrials Research, McMaster University, University of Calgary, Probity Medical Research, Universitat Autònoma de Barcelona, Hospital de Sant Pau, University of Naples Federico II, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Verona, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, University of Campania "Luigi Vanvitelli", University of Florence, Sunnybrook Health Science Centre, University Hospital of Basel, University Hospital Zurich, University of Padua, University of Zurich, Women's College Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4412725534
